Charles Zhou
Stock Analyst at UBS
(0.68)
# 3,671
Out of 4,818 analysts
10
Total ratings
42.86%
Success rate
-15.04%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Charles Zhou
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FUTU Futu Holdings | Maintains: Buy | $130 → $136 | $93.80 | +45.00% | 3 | Mar 17, 2025 | |
| ZYME Zymeworks | Reiterates: Buy | $16 | $12.49 | +28.10% | 1 | Mar 8, 2023 | |
| COGT Cogent Biosciences | Initiates: Buy | $15 | $4.52 | +232.23% | 1 | Jun 28, 2022 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.80 | - | 1 | May 5, 2022 | |
| PMVP PMV Pharmaceuticals | Initiates: Buy | $56 | $1.08 | +5,085.19% | 1 | Aug 2, 2021 | |
| RPTX Repare Therapeutics | Initiates: Buy | $46 | $1.33 | +3,358.65% | 1 | Jun 28, 2021 | |
| QD Qudian | Downgrades: Neutral | n/a | $2.65 | - | 2 | Jan 22, 2020 |
Futu Holdings
Mar 17, 2025
Maintains: Buy
Price Target: $130 → $136
Current: $93.80
Upside: +45.00%
Zymeworks
Mar 8, 2023
Reiterates: Buy
Price Target: $16
Current: $12.49
Upside: +28.10%
Cogent Biosciences
Jun 28, 2022
Initiates: Buy
Price Target: $15
Current: $4.52
Upside: +232.23%
MacroGenics
May 5, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.80
Upside: -
PMV Pharmaceuticals
Aug 2, 2021
Initiates: Buy
Price Target: $56
Current: $1.08
Upside: +5,085.19%
Repare Therapeutics
Jun 28, 2021
Initiates: Buy
Price Target: $46
Current: $1.33
Upside: +3,358.65%
Qudian
Jan 22, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.65
Upside: -